Multi-omics biomarker detection in Diethylnitrosamine (DENA) induced hepatocellular carcinoma
Clinica Chimica Acta · 2026-05 · 587 · 120937
DOI: 10.1016/j.cca.2026.120937 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinica Chimica Acta, 2026-05. Verfasst von Obaid Afzal und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, College of Pharmacy, Prince Sattam bin Abdulaziz University, Al-Kharj 11942, Saudi Arabia. Electronic address…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Biomarkers, Tumor, Diethylamines. Die Arbeit nennt 85 Literaturangaben. Gefördert von: Prince Sattam bin Abdulaziz University.
Abstract (Originalsprache)
Hepatocellular carcinoma (HCC) is frequently diagnosed at an advanced stage due to tumor heterogeneity and chronic liver damage, which reduce the performance of single biomarkers and complicate the clinical interpretation of laboratory results. The genotoxic diethylnitrosamine (DENA)-induced hepatocarcinogenesis model provides a stage-resolved and experimentally controlled framework associated with genotoxic stress, inflammation, and fibrosis, along with metabolic adaptation in target tissues and circulating biofluids. This review summarizes multi-omics data from DENA models and translational cohorts, encompassing genomics/epigenomics, transcriptomics, proteomics, metabolomics, and glycomics, as well as liquid biopsy analytes, including cell-free DNA, extracellular vesicle cargo, and circulating tumor cell markers. We integrated the dynamics of injury progression to fibrosis and tumor development at the pathway scale, highlighting multi-analyte biomarker sets that improve the differentiation between advanced fibrosis/cirrhosis and early hepatocellular carcinoma (HCC). Additionally, we examined enabling technologies in analytical techniques, including targeted mass spectrometry (MS), PCR-based methods, and clinically scalable glycoprofiling. Notably, we propose a stage-aware biomarker selection paradigm that emphasizes mechanistic consistency, analytical viability, and clinical actionability to facilitate earlier identification and longitudinal tracking. Finally, we discuss the practical implications of multicenter validation and a harmonized study design to enhance reproducibility and expedite clinical translation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Chemistry, College of Pharmacy, Prince Sattam bin Abdulaziz University, Al-Kharj 11942, Saudi Arabia. Electronic address: o.akram@psau.edu.sa.
- Dr DY Patil Medical College, Hospital and Research Centre, Pimpri, Pune, India.
- Sharda University, Greater Noida, India.
- Department of Pharmaceutical Chemistry, College of Pharmacy, Prince Sattam bin Abdulaziz University, Al-Kharj 11942, Saudi Arabia.
- Department of Pharmacology, Teerthanker Mahaveer College of Pharmacy, Teerthanker Mahaveer University, Moradabad 244001, Uttar Pradesh, India.
Förderung
- Prince Sattam bin Abdulaziz University
Zitieren
APA
Afzal, O., Goud, P., Goyal, K., Altharawi, A., Alamri, M. A., Alossaimi, M. A., Altamimi, A. S. A., & Pandey, S. N. (2026). Multi-omics biomarker detection in Diethylnitrosamine (DENA) induced hepatocellular carcinoma. Clinica Chimica Acta, 587, 120937. https://doi.org/10.1016/j.cca.2026.120937
Vancouver
Afzal O, Goud P, Goyal K, Altharawi A, Alamri MA, Alossaimi MA, et al. Multi-omics biomarker detection in Diethylnitrosamine (DENA) induced hepatocellular carcinoma. Clinica Chimica Acta. 2026;587:120937. doi:10.1016/j.cca.2026.120937
BibTeX
@article{Afzal2026,
author = {Afzal, Obaid and Goud, Pavan and Goyal, Kavita and Altharawi, Ali and Alamri, Mubarak A and Alossaimi, Manal A and Altamimi, Abdulmalik S A and Pandey, Surya Nath},
title = {Multi-omics biomarker detection in Diethylnitrosamine (DENA) induced hepatocellular carcinoma},
journal = {Clinica Chimica Acta},
year = {2026},
volume = {587},
pages = {120937},
doi = {10.1016/j.cca.2026.120937}
}
EUVIMED